Current Medical Research and Opinion

(ISSN: 0300-7995)

2009 - 25 (7)

  • Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. 
  • Control of asthma for reducing the risk of bronchospasm in asthmatics undergoing general anesthesia and/or intravascular administration of radiographic contrast media. 
 
 
 
Medscape    MedscapeCME    eMedicine    Drugs    MEDLINE    All
All material on this website is protected by copyright, Copyright © 1994-2009 by Medscape. This website also contains material copyrighted by 3rd parties.